ArticleCell death & disease2017

Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT.

Qiuli Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.